Please use this identifier to cite or link to this item:
Title: Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe
Other Titles: Arquivos Brasileiros de Cardiologia
Authors: Garcia, Maristela Magnavita Oliveira
Varela, Carolina Garcez
Silva, Patricia Fontes
Lima, Paulo Roberto Passos
Góes, Paulo Meira
Rodrigues, Marilia Galeffi
Silva, Maria de Lourdes Lima Souza e
Ladeia, Ana Marice Teixeira
Guimarães, Armênio Costa
Correia, Luis Claudio Lemos
Keywords: Endothelium / physiology; Cholesterol; Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use; Ezetimibe; Anticholesterolemic Agents.
Issue Date: Apr-2016
Abstract: Background: The effect of statins on the endothelial function in humans remains under discussion. Particularly, it is still unclear if the improvement in endothelial function is due to a reduction in LDL-cholesterol or to an arterial pleiotropic effect. Objective: To test the hypothesis that modulation of the endothelial function promoted by statins is primarily mediated by the degree of reduction in LDL-cholesterol, independent of the dose of statin administered. Methods: Randomized clinical trial with two groups of lipid-lowering treatment (16 patients/each) and one placebo group (14 patients). The two active groups were designed to promote a similar degree of reduction in LDL-cholesterol: the first used statin at a high dose (80 mg, simvastatin 80 group) and the second used statin at a low dose (10 mg) associated with ezetimibe (10 mg, simvastatin 10/ezetimibe group) to optimize the hypolipidemic effect. The endothelial function was assessed by flow-mediated vasodilation (FMV) before and 8 weeks after treatment. Results: The decrease in LDL-cholesterol was similar between the groups simvastatin 80 and simvastatin 10/ezetimibe (27% ± 31% and 30% ± 29%, respectively, p = 0.75). The simvastatin 80 group presented an increase in FMV from 8.4% ± 4.3% at baseline to 11% ± 4.2% after 8 weeks (p = 0.02). Similarly, the group simvastatin 10/ezetimibe showed improvement in FMV from 7.3% ± 3.9% to 12% ± 4.4% (p = 0.001). The placebo group showed no variation in LDL-cholesterol level or endothelial function. Conclusion: The improvement in endothelial function with statin seems to depend more on a reduction in LDL-cholesterol levels, independent of the dose of statin administered, than on pleiotropic mechanisms.
ISSN: 0066-782
Appears in Collections:Artigos Completos Publicados em Periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO - MARISTELA MAGNAVITA - 2016.pdf405,81 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.